Prostate cancer recurrence is common after radical radiotherapy and the increasing use of novel, minimally invasive salvage treatments means that accurate detection and localization of radiorecurrent disease is vital in treatment planning and delivery. PET–CT is increasingly used to detect metastatic disease; however, data regarding its value for identifying and accurately characterizing intraprostatic recurrence need improvement.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
National Prostate Cancer Audit. NPCA Annual Report 2020 (National Prostate Cancer Audit, 2021).
Zumsteg, Z. S. et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur. Urol. 67, 1009–1016 (2015).
Gaur, S. & Turkbey, B. Prostate MR imaging for posttreatment evaluation and recurrence. Radiol. Clin. North Am. 56, 263–275 (2018).
Shah, T. T. et al. Magnetic resonance imaging and targeted biopsies compared to transperineal mapping biopsies before focal ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Eur. Urol. 81, 598–605 (2022).
Crocerossa, F. et al. Detection rate of prostate specific membrane antigen tracers for positron emission tomography/computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis. J. Urol. 205, 356–369 (2021).
Valle, L. F. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur. Urol. 80, 280–292 (2021).
Kanthabalan, A. et al. Intraprostatic cancer recurrence following radical radiotherapy on transperineal template mapping biopsy: implications for focal ablative salvage therapy. J. Urol. 204, 950–955 (2020).
Golbari, N. M. & Katz, A. E. Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review. Curr. Urol. Rep. 18, 63 (2017).
Fendler, W. P. et al. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur. J. Nucl. Med. Mol. Imaging 48, 501–508 (2021).
Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. 77, 403–417 (2020).
H.U.A. receives core funding from the UK National Institute of Health Research (NIHR) Imperial Biomedical Research Centre, the Wellcome Trust, the UK NIHR, the UK Medical Research Council, Cancer Research UK, Prostate Cancer UK, The Urology Foundation, the BMA Foundation, Imperial Healthcare Charity, Sonacare, Trod Medical and Sophiris Biocorp; has received a travel allowance from Sonacare; was a paid consultant for Sophiris Biocorp and Sonacare; and is a proctor for Rezūm treatment and cryotherapy for Boston Scientific. The other authors declare no competing interests.
About this article
Cite this article
Light, A., Ahmed, H.U. & Shah, T.T. The unclear role of PET–CT in localized radiorecurrent prostate cancer. Nat Rev Urol 19, 573–574 (2022). https://doi.org/10.1038/s41585-022-00635-9